Cargando…

TP53 intron 6 polymorphism and the risk of ovarian and breast cancer.

Detalles Bibliográficos
Autores principales:	Mavridou, D., Gornall, R., Campbell, I. G., Eccles, D. M.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1998
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2149940/ https://www.ncbi.nlm.nih.gov/pubmed/9484829

Ejemplares similares

Intronic TP53 Polymorphisms Are Associated with Increased Δ133TP53 Transcript, Immune Infiltration and Cancer Risk
por: Eiholzer, Ramona A., et al.
Publicado: (2020)

Intronic TP53 Germline Sequence Variants Modify the Risk in German Breast/Ovarian Cancer Families
por: Liu, Xuan, et al.
Publicado: (2004)

No association of a 306-bp insertion polymorphism in the progesterone receptor gene with ovarian and breast cancer.
por: Manolitsas, T. P., et al.
Publicado: (1997)

Importance of TP53 codon 72 and intron 3 duplication 16bp polymorphisms in prediction of susceptibility on breast cancer
por: Costa, Sandra, et al.
Publicado: (2008)

Intronic SNPs of TP53 gene in chronic myeloid leukemia: Impact on drug response
por: Sailaja, K., et al.
Publicado: (2012)

Association Between the TP53 Polymorphisms and Breast Cancer Risk: An Updated Meta-Analysis
por: Zhao, Lin, et al.
Publicado: (2022)

Somatic intronic TP53 c.375+5G mutations are a recurrent but under‐recognized mode of TP53 inactivation
por: Chui, M Herman, et al.
Publicado: (2021)

A meta-analysis of cancer risk associated with the TP53 intron 3 duplication polymorphism (rs17878362): geographic and tumor-specific effects
por: Sagne, C, et al.
Publicado: (2013)

TP53 rs1042522 polymorphism and early-onset breast cancer
por: Icen-Taskin, Irmak, et al.
Publicado: (2020)

Studies of TP53 haplotypes in relation to LOH and TP53 mutations in breast cancer patients
por: Langerød, A, et al.
Publicado: (2000)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

Association of the TP53 codon 72 polymorphism and breast cancer risk: a meta-analysis
por: Gonçalves, Meire Luzia, et al.
Publicado: (2014)

Survival of patients with structurally-grouped TP53 mutations in ovarian and breast cancers
por: Seagle, Brandon-Luke L., et al.
Publicado: (2015)

Association of intron microsatellite status and exon mutational profiles of TP53 in human colorectal cancer
por: Liu, Xin, et al.
Publicado: (2019)

Effects of MDM2, MDM4 and TP53 Codon 72 Polymorphisms on Cancer Risk in a Cohort Study of Carriers of TP53 Germline Mutations
por: Fang, Shenying, et al.
Publicado: (2010)

Breast cancer in patients with germline TP53 pathogenic variants have typical tumour characteristics: the Cohort study of TP53 carrier early onset breast cancer (COPE study)
por: Packwood, Kate, et al.
Publicado: (2019)

The Consequence of Oncomorphic TP53 Mutations in Ovarian Cancer
por: Brachova, Pavla, et al.
Publicado: (2013)

MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status.
por: Foulkes, W. D., et al.
Publicado: (1995)

The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes
por: McGraw, K L, et al.
Publicado: (2015)

BRCA1 polymorphisms.
por: Campbell, I. G., et al.
Publicado: (1997)

No association between TP53 Arg72Pro polymorphism and ovarian cancer risk: evidence from 10113 subjects
por: Zhang, Anqi, et al.
Publicado: (2017)

Somatic Mutations of TP53 and Prognostic Factors for Primary Operable Breast Cancer: Correspondence
por: Sookaromdee, Pathum, et al.
Publicado: (2022)

Progesterone receptor gene polymorphism and risk for breast and ovarian cancer.
por: Lancaster, J. M., et al.
Publicado: (1998)

Importance of TP53 codon 72 and intron 3 duplication 16 bp polymorphisms and their haplotypes in susceptibility to sarcopenia in Iranian older adults
por: Montazeri-Najafabady, Nima, et al.
Publicado: (2022)

TP53 and MDM2 polymorphisms and the risk of endometrial cancer in postmenopausal women
por: Zając, Agnieszka, et al.
Publicado: (2014)

Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA
por: Li, Xuerui, et al.
Publicado: (2020)

Expression signatures of TP53 mutations in serous ovarian cancers
por: Bernardini, Marcus Q, et al.
Publicado: (2010)

Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma
por: Köbel, Martin, et al.
Publicado: (2016)

Role of TP53 polymorphisms in sub-Saharan mucosal cancers
por: Buonaguro, Franco M, et al.
Publicado: (2010)

Analysis of Tp53 Codon 72 Polymorphisms, Tp53 Mutations, and HPV Infection in Cutaneous Squamous Cell Carcinomas
por: Loeb, Keith R., et al.
Publicado: (2012)

Association of TP53 gene codon 72 polymorphism with endometriosis risk in Isfahan
por: Nikbakht Dastjerdi, Mehdi, et al.
Publicado: (2013)

Prognostic value genotypes and LOH at TP53 codon 72 and TP53 mutations in primary breast cancer
por: Kyndi, M, et al.
Publicado: (2005)

No association of TP53 codon 72 and intron 3 16-bp duplication polymorphisms with breast cancer risk in Chinese Han women: new evidence from a population-based case–control investigation
por: Hao, Weiming, et al.
Publicado: (2018)

TP53 intron 1 hotspot rearrangements are specific to sporadic osteosarcoma and can cause Li-Fraumeni syndrome
por: Ribi, Sebastian, et al.
Publicado: (2015)

Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients
por: Toyama, Tatsuya, et al.
Publicado: (2007)

TP53 and XRCC1 polymorphisms and breast cancer prognosis: a case-case study
por: Rodrigues, Marina Silva, et al.
Publicado: (2011)

Increased access to TP53 analysis through breast cancer multi-gene panels: clinical considerations
por: Azzollini, Jacopo, et al.
Publicado: (2017)

Polymorphisms of TP53 codon 72 with breast carcinoma risk: evidence from 12226 cases and 10782 controls
por: Zhuo, Wenlei, et al.
Publicado: (2009)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Impact of TP53 mutations in Triple Negative Breast Cancer
por: Mitri, Zahi I., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1nmk18h64ilnh5b1jfitivqjpj